Journal: PLoS ONE

Article Title: Targeted Mutation of the Mouse Grp94 Gene Disrupts Development and Perturbs Endoplasmic Reticulum Stress Signaling

doi: 10.1371/journal.pone.0010852

Figure Lengend Snippet: (A) Representative Western blot results on effect of GRP94 depletion on cell proliferation and apoptosis. Grp94 +/+ and −/− ESCs were treated with 300 nM Tg for the indicated time (hr). The whole cell lysates were subjected to Western blot with antibodies against PCNA, caspase-7 (C-7) and β-actin. Both pro C-7 (the uncleaved form) and cleaved C-7 (active form) were detected by the anti-C-7 antibody. The cleaved C-7 protein level was quantitated and normalized against β-actin. The level of cleaved C-7 in Grp94 +/+ ESCs treated with Tg for 4 hr was set as 1. (B) The same as in (A) with 1.5 µg/ml Tunicamycin (Tu) treated cells. The Western blots were performed with antibodies against cleaved caspase-3 (C-3) and β-actin. The cleaved C-3 protein level was quantitated and normalized against β-actin. The level of cleaved C-3 in Grp94 +/+ ESCs without Tu treatment was set as 1. These experiments were repeated two times.

Article Snippet: The primary antibodies used included the following: mouse anti-KDEL(10C3) (1∶1000), rat anti-GRP94 (1∶2500), rabbit anti-calnexin (1∶2000), and rabbit anti-calreticulin (1∶2000) from Stressgen; goat anti-GRP78(C20) (1∶5000), rabbit anti-PERK (H-300) (1∶500), rabbit anti-ATF4 (CREB-2) (1∶1000), goat anti-HSP70 (K-20) (1∶1000), mouse anti-PCNA (PC10) (1∶1000), mouse anti-CHOP (1∶1000), goat anti-EDEM (1∶500) and rabbit anti-XBP1 (1∶500) from Santa Cruz Biotechnology; rabbit anti-phospho-PERK (Thr980) (1∶500), mouse anti-cleaved-caspase-7 (Asp198), rabbit anti-phospho-eIF2α (1∶1000), rabbit anti- eIF2α (1∶1000) and rabbit anti-cleaved caspase-3 (Asp175) (1∶500) from Cell Signaling; rabbit anti-PDI (1∶2000) from Assay Designs; mouse anti-β-actin (1∶5000) from Sigma-Aldrich; and rabbit anti-p62 (SQSTM1) (1∶1000) from BIOMOL.

Techniques: Western Blot

Journal: Acta Ophthalmologica

Article Title: 12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

doi: 10.1111/aos.15014

Figure Lengend Snippet: Demographic characteristics of all treatment‐naïve CRVO eyes commencing ranibizumab or aflibercept treatment 2014–2019.

Article Snippet: Baseline VA (SD) was somewhat better in aflibercept‐ versus ranibizumab‐treated eyes (42.5 ± 25.5 letters versus 36.9 ± 26 letters; p = 0.07) with similar CST (614 (240) μm versus 616 (234) μm: p = 0.95).

Techniques:

Journal: Acta Ophthalmologica

Article Title: 12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

doi: 10.1111/aos.15014

Figure Lengend Snippet: 12‐month outcomes in all eyes and stratified by anti‐VEGF agent received. Significant p‐values comparing ranibizumab and aflibercept are highlighted in bold.

Article Snippet: Baseline VA (SD) was somewhat better in aflibercept‐ versus ranibizumab‐treated eyes (42.5 ± 25.5 letters versus 36.9 ± 26 letters; p = 0.07) with similar CST (614 (240) μm versus 616 (234) μm: p = 0.95).

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway

doi: 10.3390/ijms22041882

Figure Lengend Snippet: List of antibodies used.

Article Snippet: Cleaved Caspase-7 (Asp198) (D6H1) Rabbit mAb , Cell Signaling Technology, Danvers, MA, USA (8438) , 1:400 , Anti-rabbit IgG, HRP-linked Antibody , Cell Signaling Technology, Danvers, MA, USA (7074) , 1:2000.

Techniques: